Shimamura Shoko Sonobe, Shukuya Takehito, Takahashi Kazuhisa, Shintani Yasushi, Sekine Ikuo, Takayama Koichi, Inoue Akira, Okamoto Isamu, Kawaguchi Tomoya, Yamamoto Nobuyuki, Miyaoka Etsuo, Yoshino Ichiro, Date Hiroshi
Department of Respiratory Medicine, Juntendo University, Tokyo, Japan.
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Thorac Cancer. 2025 Apr;16(8):e70060. doi: 10.1111/1759-7714.70060.
Palliative interventions, such as chest tube drainage and radiotherapy for bone and brain metastases, are crucial for managing survival and quality of life in patients with advanced lung cancer.
This retrospective study analyzed 8171 patients with unresectable Stage IV lung cancer from the Japanese Joint Committee of Lung Cancer Registry (JJCLCR) database. At treatment initiation, 8.6% of patients underwent chest tube drainage, 9.9% underwent bone radiotherapy, and 11.5% underwent brain radiotherapy. In this study, associated factors for palliative interventions were evaluated, and their impact on patient survival was also assessed.
High-associated factors for upfront chest tube drainage included age ≥ 75 years, ECOG-PS ≥ 2, pleural nodules, and adenocarcinoma, while EGFR mutation, serum albumin ≥ 3.2 mg/dL, adrenal gland, and brain metastases were low-associated factors. For upfront brain radiotherapy, low-associated factors included malignant pleural effusion (MPE) and bone metastases, whereas ECOG-PS ≥ 2 was a high-associated factor. High-associated factors for upfront bone radiotherapy were serum albumin ≥ 3.2 mg/dL, ECOG-PS ≥ 2, adenocarcinoma, and squamous cell carcinoma, while pleural nodules, MPE, liver, and brain metastasis were low-associated factors. Patients receiving upfront bone radiotherapy had shorter survival, whereas survival did not significantly differ for those with or without upfront chest tube drainage or brain radiotherapy.
This study identified associated factors for palliative interventions in advanced lung cancer and their association with overall survival. Future prospective studies with more detailed data are necessary to confirm these findings and improve clinical decision-making.
Approval No. 15,321.
姑息性干预措施,如胸腔闭式引流以及针对骨和脑转移的放射治疗,对于晚期肺癌患者的生存管理和生活质量至关重要。
这项回顾性研究分析了日本肺癌登记联合委员会(JJCLCR)数据库中8171例不可切除的IV期肺癌患者。在开始治疗时,8.6%的患者接受了胸腔闭式引流,9.9%接受了骨放射治疗,11.5%接受了脑放射治疗。在本研究中,评估了姑息性干预的相关因素,并评估了它们对患者生存的影响。
前期胸腔闭式引流的高相关因素包括年龄≥75岁、东部肿瘤协作组(ECOG)体能状态评分≥2、胸膜结节和腺癌,而表皮生长因子受体(EGFR)突变、血清白蛋白≥3.2mg/dL、肾上腺和脑转移是低相关因素。对于前期脑放射治疗,低相关因素包括恶性胸腔积液(MPE)和骨转移,而ECOG体能状态评分≥2是高相关因素。前期骨放射治疗的高相关因素是血清白蛋白≥3.2mg/dL、ECOG体能状态评分≥2、腺癌和鳞状细胞癌,而胸膜结节、MPE、肝和脑转移是低相关因素。接受前期骨放射治疗的患者生存期较短,而接受或未接受前期胸腔闭式引流或脑放射治疗的患者生存期无显著差异。
本研究确定了晚期肺癌姑息性干预的相关因素及其与总生存期的关联。需要未来进行更详细数据的前瞻性研究来证实这些发现并改善临床决策。
批准号15,321。